»
Current State of Alzheimer's Disease Research and Therapeutics
 
 

Current State of Alzheimer's Disease Research and Therapeutics, 1st Edition

 
Current State of Alzheimer's Disease Research and Therapeutics, 1st Edition,Mary Lou Michaelis,Elias K. Michaelis,ISBN9780123948168
 
 
 

Advances in Pharmacology

Michaelis   &   Michaelis   

Academic Press

9780123948168

9780123948458

400

229 X 152

This new volume of Advances in Pharmacology explores the current state of Alzheimer's disease research and therapeutics. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Print Book + eBook

USD 303.00
USD 505.00

Buy both together and save 40%

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 256.00

eBook
eBook Overview

VST (VitalSource Bookshelf) format

DRM-free included formats : EPUB, Mobi (for Kindle), PDF

USD 249.00
Add to Cart
 
 

Key Features

  • Explores the current state of Alzheimer's disease research and therapeutics
  • Chapters cover a variety of topics such as the role heat shock proteins play in the Alzheimer's theater, gamma-secretase as a target for Alzheimer's disease, and identification of protein kinase C for the treatment of dementias
  • With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike

Description

This new volume of Advances in Pharmacology explores the Current State of Alzheimer's Disease Research and Therapeutics. Chapters cover such topics as the The role heat shock proteins play in the Alzheimer's Theater, Gamma-Secretase as a Target for Alzheimer's Disease, and Identification of protein kinase C for the treatment of dementias. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Readership

Pharmacologists, immunologists, and biochemists

Information about this author is currently not available.
Information about this author is currently not available.

Current State of Alzheimer's Disease Research and Therapeutics, 1st Edition

Contributors

Hsp90 Modulation for the Treatment of Alzheimer’s Disease

I Introduction

II Hsp90 Complexes in Alzheimer’s Disease

III Potential Therapeutic Effects of Hsp90 Inhibitors in Alzheimer’s Disease

IV Conclusion

Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta

I Introduction

II Rationale for Studying Amyloid Deposition

III General Properties of the Aß Imaging Tracer, PiB

IV Early Human PiB Studies

V Amyloid Imaging and Apolipoprotein-E Genotype

VI Amyloid Imaging in Normal Controls

VII Amyloid Imaging in MCI

VIII Amyloid Deposition in Early-Onset, Autosomal Dominant, Familial AD

IX Frontotemporal Dementia

X Dementia with Lewy Bodies and Parkinson’s Disease

XI Cerebral Amyloid Angiopathy (CAA)

XII Atypical Presentations of AD

XIII Postmortem Validation of PiB-PET Imaging

XIV Amyloid Imaging Compared to Other Biomarkers

XV Amyloid Imaging in AD Drug Development

XVI F-18 Compounds

XVII Detection of the Earliest Signs of Amyloid Deposition

XVIII Limitations, Validity, and Unresolved Questions

XIX Conclusion

List of Abbreviations

Mitochondrial Abnormalities in Alzheimer’s Disease

I Introduction

II Mitochondrial Function in AD

III Mitochondria as a Therapeutic Target in AD

IV Conclusion

Abbreviations

?-Secretase as a Target for Alzheimer’s Disease

I Introduction

II ?-Secretase in Alzheimer’s Disease

III ?-Secretase in Biology

IV Biochemistry of the ?-Secretase Complex

V Inhibitors

VI Modulators

VII Conclusion

Abbreviations

Altering Mitochondrial Dysfunction as an Approach to Treating Alzheimer’s Disease

I Introduction

II Theories of Pathogenesis and the Natural History of Alzheimer’s Disease

III Other Pathologies Can Affect Mitochondrial Function

IV Mitochondrial Function Can Exacerbate Other Pathology

V Therapeutic Approaches Being Taken and Opportunities Suggested

VI Conclusion

Abbreviations

scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer’s Disease

I Introduction

II Preclinical Development of scyllo-Inositol

III Sources of scyllo-Inositol

IV Bioavailability and Metabolism

V Human Clinical Trials of scyllo-Inositol as an AD Therapeutic

VI Structure–Function Analysis of scyllo-Inositol

VII Inositol for the Treatment of Other Disorders

VIII Conclusion

Abbreviations

Beyond Amyloid

I Introduction

II Current Therapeutic Targets

III Conclusion

Abbreviations

Activation of Protein Kinase C Isozymes for the Treatment of Dementias

I Introduction

II PKC Signaling System

III Memory and Alzheimer’s Dementia

IV Ischemic Dementia

V Conclusion

Abbreviations

Striatal-Enriched Protein Tyrosine Phosphatase in Alzheimer’s Disease

I Introduction

II Striatal-Enriched Protein Tyrosine Phosphatase (STEP)

III STEP Inhibitors

IV Conclusion

Abbreviations

Estrogen Regulation of Mitochondrial Bioenergetics

I Introduction: Alzheimer’s Disease—Unlimited Cost/Limited Windows of Therapeutic Opportunity

II Role of Mitochondrial Bioenergetics in Alzheimer’s Pathogenesis

III Estrogen Action in the Brain-Convergence upon Mitochondrial Bioenergetics and Brain Metabolism

IV Healthy Cell Bias of Estrogen Action: Consolidation of Clinical Observations and Basic Mechanistic Discoveries

V Clinical Implications for Biomarker Identification and Therapeutic Development for Alzheimer’s Disease

VI Conclusion

Abbreviations

Index

Recent Volumes in the Serial

 
 
Free Shipping
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us